Therapy Areas: Inflammatory Diseases
Bambusa Therapeutics prices upsized initial public offering
30 October 2026 - Bambusa Therapeutics Inc (Nasdaq:BBTX), a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies for immunology and inflamma...
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
28 October 2026 - Computational chemistry company Evogene Ltd (NASDAQ: EVGN) (TASE: EVGN) announced on Wednesday that it has selected acute graft-versus-host disease (aGVHD) as the target indication f...
Lynk Pharmaceuticals reports positive Phase III trial results for zemprocitinib in rheumatoid arthritis
28 October 2026 - Lynk Pharmaceuticals Co Ltd, a Chinese drug development company focused on immune and inflammatory diseases, on Tuesday announced positive long-term results from its pivotal Phase II...
Cumberland Pharmaceuticals to submit New Drug Application for ifetroban
27 October 2026 - US biopharmaceutical company Cumberland Pharmaceuticals Inc (Nasdaq: CPIX) announced on Monday that it plans to submit a New Drug Application (NDA) to the US Food and Drug Administra...
Alnylam reports positive Phase 1b results for brezosiran in Huntington's disease
23 October 2026 - RNAi (RNA interference) therapeutics company Alnylam Pharmaceuticals Inc (Nasdaq:ALNY) on Friday reported positive initial Phase 1b clinical trial results for brezosiran, an investig...
European Commission approves Novartis' Cosentyx for polymyalgia rheumatica
21 October 2026 - Swiss pharmaceutical company Novartis AG (SIX: NOVN; NYSE: NVS) on Wednesday said the European Commission has approved Cosentyx (secukinumab) for adults with polymyalgia rheumatica (...